Publicacions en què col·labora amb Joaquín Díaz Mediavilla (11)

2016

  1. Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia

    Leukemia Research, Vol. 40, pp. 1-9

2013

  1. A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control

    Leukemia, Vol. 27, Núm. 10, pp. 2056-2061

  2. Erratum: A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control (Leukemia (2013) 27 (2112))

    Leukemia

2012

  1. Multiparameter flow cytometry evaluation of plasma cell DNA content and proliferation in 595 transplant-eligible patients with myeloma included in the Spanish GEM2000 and GEM2005<65y trials

    American Journal of Pathology, Vol. 181, Núm. 5, pp. 1870-1878

2008

  1. Prognostic value of immunophenotyping in multiple myeloma: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy

    Journal of Clinical Oncology, Vol. 26, Núm. 16, pp. 2737-2744

2006

  1. Heterogeneity of neoplastic cells in B-cell chronic lymphoproliferative disorders: Biclonality versus intraclonal evolution of a single tumor cell clone

    Haematologica, Vol. 91, Núm. 3, pp. 331-339

2005

  1. Discrimination of biclonal B-cell chronic lymphoproliferative neoplasias by tetraspanin antigen expression [18]

    Leukemia

  2. Genetic abnormalities and patterns of antigenic expression in multiple myeloma

    Clinical Cancer Research, Vol. 11, Núm. 10, pp. 3661-3667

2002

  1. Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome

    Blood, Vol. 99, Núm. 5, pp. 1853-1856

2001

  1. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification

    Blood, Vol. 98, Núm. 6, pp. 1746-1751

1997

  1. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients

    Blood, Vol. 90, Núm. 6, pp. 2465-2470